SMILES string
S1\C(=N/CCC)\N(C(=O)\C\1=C\c3cc(c(cc3)OC[C@H](O)CO)Cl)c2c(cccc2)C
InChI
1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23-/t17-/m1/s1
InChI key
LPAUOXUZGSBGDU-STDDISTJSA-N
assay
≥95% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Orally active, potent and subtype-selective sphingosine-1-phosphate (S1P) receptor S1P1 agonist.
Ponesimod (ACT-128800) is an orally active, potent and subtype-selective sphingosine-1-phosphate (S1P) receptor agonist (human S1P1/2/3/4/5 EC50 = 5.7 nM/>10 µM/105 nM/1.108 µM/59.1 nM by 35S-GTPγ binding, 6.0 nM/>10 µM/2.068 µM/1.956 µM/142 nM by 33P-S1P binding). Ponesimod oral administration causes a significant decrease in peripheral lymphocyte counts in rats in vivo (by 65-75% 3h post 3 mg/kg).
Ponesimod (ACT-128800) is an orally active, potent and subtype-selective sphingosine-1-phosphate (S1P) receptor agonist (human S1P1/2/3/4/5 EC50 = 5.7 nM/>10 µM/105 nM/1.108 µM/59.1 nM by 35S-GTPγ binding, 6.0 nM/>10 µM/2.068 µM/1.956 µM/142 nM by 33P-S1P binding). Ponesimod oral administration causes a significant decrease in peripheral lymphocyte counts in rats in vivo (by 65-75% 3h post 3 mg/kg).
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Martin H Bolli et al.
Journal of medicinal chemistry, 53(10), 4198-4211 (2010-05-08)
Sphingosine-1-phosphate (S1P) is a widespread lysophospholipid which displays a wealth of biological effects. Extracellular S1P conveys its activity through five specific G-protein coupled receptors numbered S1P(1) through S1P(5). Agonists of the S1P(1) receptor block the egress of T-lymphocytes from thymus
Zhihui Zhu et al.
EBioMedicine, 94, 104713-104713 (2023-07-23)
Previously, we showed that the sphingosine-1-phosphate (S1P) transporter spinster 2 (Spns2) mediates activation of microglia in response to amyloid β peptide (Aβ). Here, we investigated if Ponesimod, a functional S1P receptor 1 (S1PR1) antagonist, prevents Aβ-induced activation of glial cells
Yasuyuki Kihara et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 36(2), e22132-e22132 (2022-01-06)
Ponesimod is a sphingosine 1-phosphate (S1P) receptor (S1PR) modulator that was recently approved for treating relapsing forms of multiple sclerosis (MS). Three other FDA-approved S1PR modulators for MS-fingolimod, siponimod, and ozanimod-share peripheral immunological effects via common S1P1 interactions, yet ponesimod
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持